Navigation auf uzh.ch
Navigation auf uzh.ch
Research paper by Beatriz Achón Buil, Christian Tackenberg, Ruslan Rust published in Brain
Stem cell therapy has been shown to improve stroke outcomes in animal models and is currently advancing towards clinical practice. However, uncertainty remains regarding the optimal route for cell delivery to the injured brain. Local intracerebral injections are effective in precisely delivering cells into the stroke cavity but carry the risk of damaging adjacent healthy tissue.
Systemic endovascular injections, meanwhile, are minimally invasive, but most injected cells do not cross central nervous system (CNS) barriers and become mechanically trapped in peripheral organs. Although the blood–brain barrier (BBB) and the blood–cerebrospinal fluid barrier (BCSFB) tightly limit the entrance of cells and molecules into the brain parenchyma, immune cells can cross these barriers especially under pathological conditions, such as stroke.
Deciphering the cell surface signature and the molecular mechanisms underlying this pathophysiological process holds promise for improving the targeted delivery of systemic injected cells to the injured brain. In this review, we describe experimental approaches that have already been developed in which (a) cells are either engineered to express cell surface proteins mimicking infiltrating immune cells or (b) cell grafts are preconditioned with hypoxia or incubated with pharmacological agents or cytokines.
Modified cell grafts can be complemented with strategies to temporarily increase the permeability of the blood–brain barrier. Although these approaches could significantly enhance homing of stem cells into the injured brain, cell entrapment in off-target organs remains a non-negligible risk. Recent developments in safety-switch systems, which enable the precise elimination of transplanted cells upon the administration of a drug, represent a promising strategy for selectively removing stem cells stuck in untargeted organs.
In sum, the techniques described in this review hold great potential to substantially improve efficacy and safety of future cell therapies in stroke and may be relevant to other brain diseases.
Original Article here: https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awac393/6832391
